Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate is claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein. Additionally, the company is developing DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. These therapies aim to address unmet medical needs in autoimmune conditions by modulating key immune pathways.

Dianthus Therapeutics, Inc. is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol DNTH. The stock trades in U.S. dollars (USD), which is the official currency of the United States where the exchange is based. Investors can buy and sell shares of DNTH on this exchange during regular trading hours, and the company's financial reporting is conducted in USD.

Dianthus Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on researching and developing innovative therapies, particularly for severe autoimmune diseases. The biotechnology industry involves using biological processes and living organisms to create medical treatments, and Dianthus is a clinical-stage player in this field, meaning its products are still undergoing clinical trials and have not yet received regulatory approval for commercial sale.

Dianthus Therapeutics is headquartered in New York, New York, United States. The company was founded in 2019, making it a relatively young biotechnology firm. Its operations are based in the U.S., and it primarily serves the American market, though autoimmune diseases are a global health concern. The company's location in New York provides access to a major financial and biomedical research hub, which supports its clinical development activities and potential partnerships.

Dianthus Therapeutics has two main product candidates in its pipeline. The lead candidate is claseprubart, a monoclonal antibody designed with an extended half-life, improved potency, and high selectivity for only the active C1s complement protein, which is involved in the complement system of the immune response. The second candidate is DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Both candidates are being developed for severe autoimmune diseases, aiming to provide more targeted and effective treatments.